Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The European Federation for Pharmaceutical Sciences (EUFEPS) today awarded the Giorgio Segré Prize to Professor Joel Tarning for his scientific research work on the pharmacokinetic and pharmacodynamic properties of antimalarial drugs in vulnerable populations, such as pregnant women and young children.

Joel Tarning

Based in Bangkok, Thailand, Professor Tarning leads a diverse team of 30 scientists studying clinical pharmacology at the Mahidol Oxford Tropical Medicine Research Unit (MORU), a research collaboration between Mahidol University in Thailand and Oxford University and the Wellcome Trust in the UK. The team has responsibilities within pharmacometric data analysis, bioanalytical method development, drug quantification of clinical samples and omics-based research. Professor Tarning is also the Head of the Pharmacometric Modelling Group at the Worldwide Antimalarial Resistance Network (WWARN).

The main focus of Professor Tarning’s research is antimalarial dose-optimisation in vulnerable populations at risk of treatment failure and resistance development, such as children and pregnant women. He has built a group that develops and uses integrated models for disease transmission, parasite dynamics, drug action, resistance development, pharmacokinetics and patient population characteristics.

“Dr Tarning has demonstrated that he can integrate trial design, data collection and data analysis to respond to a trial aim and also contribute to defining this aim, knowledgeably and efficiently” noted the EUFEPS in its award statement. “His work on population pharmacokinetic-pharmacodynamic modelling of oral dihydroartemisinin-piperaquine in children with uncomplicated malaria, and intramuscular artesunate in children with severe malaria, started the debate on new dose recommendations in young children which has informed revised WHO guidelines for the treatment of malaria."

Based in Järfälla, Sweden, EUFEPS serves and advances excellence in the pharmaceutical sciences and innovative drug research in Europe. Founded in 1991, EUFEPS publishes European Journal of Pharmaceutical Sciences, its monthly official scientific journal. The Giorgio Segré Prize is awarded by EUFEPS on a biennial basis to young researchers who have made significant contributions to the pharmacologic discipline of pharmacokinetics-pharmacodynamics, which studies the effects in patients of administered drug doses over time.

Prof Philippe Guérin, Director of WWARN, said: “Professor Tarning’s work has made a significant contribution to our understanding of the optimal dosing for key antimalarial medicines used to treat children with malaria. The award is a fitting recognition of his work and we are delighted that the EUFPS have acknowledged its significance.”

For press enquiries, please contact:

Per Öhrngren, European Federation for Pharmaceutical Sciences (EUFEPS)

Anne Whitehouse, Worldwide Antimalarial Resistance Network (WWARN), Centre for Tropical Medicine & Global Health, University of Oxford; tel. +44(0)1865 857 412 or + 44 (0) 7812 165 934

For Asia-based MORU enquiries: John Bleho, Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand; tel. +66 81 750 0539

For the Wellcome Trust, please contact Clare Ryan; tel. +44 207 611 7262

Similar stories

Laos’ first Pint of Science: warty newts, COVID, AI for Instagram, and more!

Organised by a grass-root community of thousands of scientists across the world, Pint of Science 2022 allowed researchers in 25 countries and over 800 cities to share their latest findings with lay folk in interesting, informal settings. Lao PDR joined the global Pint of Science family on Monday 9 May, when the first-ever Pint of Science Laos kicked off!

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

PRIORITISE study team publishes results, now seeks partners

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Under the Mask, drama film based on testimonies of tuberculosis patients

In 2022, tuberculosis (TB) remains a major global health problem, particularly in developing countries. On the Thai-Myanmar border, TB is an important problem among migrants, a vulnerable, very mobile population, with unstable, often difficult living conditions, insecure incomes, and poor access to health services.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.